Pfizer’s Bourla confident in company’s obesity drug position, despite delays

Pfizer missed its first chance at following Novo Nordisk and Eli Lilly into the fast-growing market for GLP-1 obesity drugs. CEO Albert Bourla is advising investors not to count it out too quickly the second time.